Site icon Market Globalist

Why The KemPharm (KMPH) Stock Has Been Rising More Than 50% In Early Trades?

VBTX Stock

VBTX Stock

The specialty pharmaceutical company KemPharm, Inc. (NASDAQ: KMPH) has been seeing its shares skyrocketing in early trades today. As of 10:46 a.m. EST, the stock was at a rise of +57.37% to $14.84. The increase came the following approval a new drug application (NDA) by the Food and Drug Administration (FDA).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

What’s behind the surge?


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


KemPharm is an experimental drug developer dedicated to the discovery and development of novel pharmaceutical compounds to treat serious medical conditions and the development of future drug candidates through its novel LAT (Ligand Activated Therapy) technology.

KemPharm’s proprietary LAT technology enables companies to develop prodrug versions of FDA-approved drugs as well as to develop prodrug versions of already-existing compounds that could potentially treat new disease indications.

Today, KemPharm announced that the FDA has approved AZSTARYS, which is an anti-attention deficit drug for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged six and older through a single daily dose.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Exit mobile version